EP3236966 - COMBINATION OF RAF INHIBITORS AND TAXANES [Right-click to bookmark this link] | Status | No opposition filed within time limit Status updated on 18.06.2021 Database last updated on 29.10.2024 | |
Former | The patent has been granted Status updated on 10.07.2020 | ||
Former | Grant of patent is intended Status updated on 02.03.2020 | ||
Former | Request for examination was made Status updated on 29.09.2017 | ||
Former | The international publication has been made Status updated on 19.07.2017 | Most recent event Tooltip | 15.07.2022 | Lapse of the patent in a contracting state New state(s): MK, PT | published on 17.08.2022 [2022/33] | Applicant(s) | For all designated states DOT Therapeutics-1, Inc. 2765 Sand Hill Road Menlo Park, CA 94025 / US | [2020/18] |
Former [2017/44] | For all designated states Millennium Pharmaceuticals, Inc. 40 Landsdowne Street Cambridge, MA 02139 / US | Inventor(s) | 01 /
BOZON, Viviana 99 Pickwick Road West Newton, MA 02465 / US | 02 /
GALVIN, Katherine M. 52 Greenlawn Avenue Newton, MA 02459 / US | 03 /
BRAKE, Rachael L. 21 Manchester Place Natick, MA 01760 / US | 04 /
XU, Qunli 43 Nothgate Road Wellesley, MA 02481 / US | 05 /
KANNAN, Karuppiah 47 Auburn Street Newton, MA 02465 / US | [2020/33] |
Former [2017/44] | 01 /
BOZON, Viviana 99 Pickwick Road West Newton, MA 02465 / US | ||
02 /
GALVIN, Katherine, M. 52 Greenlawn Avenue Newton, MA 02459 / US | |||
03 /
BRAKE, Rachael, L. 21 Manchester Place Natick, MA 01760 / US | |||
04 /
XU, Qunli 43 Nothgate Road Wellesley, MA 02481 / US | |||
05 /
KANNAN, Karuppiah 47 Auburn Street Newton, MA 02465 / US | Representative(s) | Harris, Jennifer Lucy Kilburn & Strode LLP Lacon London 84 Theobalds Road London WC1X 8NL / GB | [2017/44] | Application number, filing date | 15874331.0 | 22.12.2015 | [2017/44] | WO2015US67462 | Priority number, date | US201462096020P | 23.12.2014 Original published format: US 201462096020 P | US201562242629P | 16.10.2015 Original published format: US 201562242629 P | [2017/44] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2016106359 | Date: | 30.06.2016 | Language: | EN | [2016/26] | Type: | A1 Application with search report | No.: | EP3236966 | Date: | 01.11.2017 | Language: | EN | The application published by WIPO in one of the EPO official languages on 30.06.2016 takes the place of the publication of the European patent application. | [2017/44] | Type: | B1 Patent specification | No.: | EP3236966 | Date: | 12.08.2020 | Language: | EN | [2020/33] | Search report(s) | International search report - published on: | US | 30.06.2016 | (Supplementary) European search report - dispatched on: | EP | 31.08.2018 | Classification | IPC: | A61K31/506, A61K31/428, A61K31/337, A61K45/06, A61P35/00, A61K31/505 | [2018/39] | CPC: |
A61K31/506 (EP,US);
A61K31/337 (EP,US);
A61K31/428 (EP,US);
A61K45/06 (EP,US);
A61P35/00 (EP,US)
| C-Set: |
A61K31/337, A61K2300/00 (EP,US);
A61K31/428, A61K2300/00 (US,EP);
A61K31/506, A61K2300/00 (US,EP)
|
Former IPC [2017/44] | A61K31/505 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2017/44] | Extension states | BA | Not yet paid | ME | Not yet paid | Validation states | MA | Not yet paid | MD | Not yet paid | Title | German: | KOMBINATION AUS RAF-HEMMERN UND TAXANEN | [2017/44] | English: | COMBINATION OF RAF INHIBITORS AND TAXANES | [2017/44] | French: | COMBINAISON D'INHIBITEURS DE RAF ET DE TAXANES | [2017/44] | Entry into regional phase | 19.07.2017 | National basic fee paid | 19.07.2017 | Search fee paid | 19.07.2017 | Designation fee(s) paid | 19.07.2017 | Examination fee paid | Examination procedure | 19.07.2017 | Examination requested [2017/44] | 19.07.2017 | Date on which the examining division has become responsible | 26.03.2019 | Amendment by applicant (claims and/or description) | 03.03.2020 | Communication of intention to grant the patent | 06.07.2020 | Fee for grant paid | 06.07.2020 | Fee for publishing/printing paid | 06.07.2020 | Receipt of the translation of the claim(s) | Opposition(s) | 14.05.2021 | No opposition filed within time limit [2021/29] | Fees paid | Renewal fee | 27.12.2017 | Renewal fee patent year 03 | 31.12.2018 | Renewal fee patent year 04 | 27.12.2019 | Renewal fee patent year 05 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | HU | 22.12.2015 | AL | 12.08.2020 | AT | 12.08.2020 | CY | 12.08.2020 | CZ | 12.08.2020 | DK | 12.08.2020 | EE | 12.08.2020 | FI | 12.08.2020 | HR | 12.08.2020 | LT | 12.08.2020 | LV | 12.08.2020 | MK | 12.08.2020 | MT | 12.08.2020 | NL | 12.08.2020 | PL | 12.08.2020 | PT | 12.08.2020 | RO | 12.08.2020 | RS | 12.08.2020 | SE | 12.08.2020 | SI | 12.08.2020 | SK | 12.08.2020 | SM | 12.08.2020 | TR | 12.08.2020 | BG | 12.11.2020 | NO | 12.11.2020 | GR | 13.11.2020 | IS | 12.12.2020 | [2022/32] |
Former [2022/27] | HU | 22.12.2015 | |
AL | 12.08.2020 | ||
AT | 12.08.2020 | ||
CY | 12.08.2020 | ||
CZ | 12.08.2020 | ||
DK | 12.08.2020 | ||
EE | 12.08.2020 | ||
FI | 12.08.2020 | ||
HR | 12.08.2020 | ||
LT | 12.08.2020 | ||
LV | 12.08.2020 | ||
MT | 12.08.2020 | ||
NL | 12.08.2020 | ||
PL | 12.08.2020 | ||
RO | 12.08.2020 | ||
RS | 12.08.2020 | ||
SE | 12.08.2020 | ||
SI | 12.08.2020 | ||
SK | 12.08.2020 | ||
SM | 12.08.2020 | ||
TR | 12.08.2020 | ||
BG | 12.11.2020 | ||
NO | 12.11.2020 | ||
GR | 13.11.2020 | ||
IS | 12.12.2020 | ||
Former [2021/36] | AL | 12.08.2020 | |
AT | 12.08.2020 | ||
CZ | 12.08.2020 | ||
DK | 12.08.2020 | ||
EE | 12.08.2020 | ||
FI | 12.08.2020 | ||
HR | 12.08.2020 | ||
LT | 12.08.2020 | ||
LV | 12.08.2020 | ||
NL | 12.08.2020 | ||
PL | 12.08.2020 | ||
RO | 12.08.2020 | ||
RS | 12.08.2020 | ||
SE | 12.08.2020 | ||
SI | 12.08.2020 | ||
SK | 12.08.2020 | ||
SM | 12.08.2020 | ||
BG | 12.11.2020 | ||
NO | 12.11.2020 | ||
GR | 13.11.2020 | ||
IS | 12.12.2020 | ||
Former [2021/28] | AL | 12.08.2020 | |
AT | 12.08.2020 | ||
CZ | 12.08.2020 | ||
DK | 12.08.2020 | ||
EE | 12.08.2020 | ||
FI | 12.08.2020 | ||
HR | 12.08.2020 | ||
LT | 12.08.2020 | ||
LV | 12.08.2020 | ||
NL | 12.08.2020 | ||
PL | 12.08.2020 | ||
RO | 12.08.2020 | ||
RS | 12.08.2020 | ||
SE | 12.08.2020 | ||
SK | 12.08.2020 | ||
SM | 12.08.2020 | ||
BG | 12.11.2020 | ||
NO | 12.11.2020 | ||
GR | 13.11.2020 | ||
IS | 12.12.2020 | ||
Former [2021/25] | AL | 12.08.2020 | |
AT | 12.08.2020 | ||
CZ | 12.08.2020 | ||
DK | 12.08.2020 | ||
EE | 12.08.2020 | ||
FI | 12.08.2020 | ||
HR | 12.08.2020 | ||
LT | 12.08.2020 | ||
LV | 12.08.2020 | ||
NL | 12.08.2020 | ||
PL | 12.08.2020 | ||
RO | 12.08.2020 | ||
RS | 12.08.2020 | ||
SE | 12.08.2020 | ||
SM | 12.08.2020 | ||
BG | 12.11.2020 | ||
NO | 12.11.2020 | ||
GR | 13.11.2020 | ||
IS | 12.12.2020 | ||
Former [2021/23] | AT | 12.08.2020 | |
CZ | 12.08.2020 | ||
DK | 12.08.2020 | ||
EE | 12.08.2020 | ||
FI | 12.08.2020 | ||
HR | 12.08.2020 | ||
LT | 12.08.2020 | ||
LV | 12.08.2020 | ||
NL | 12.08.2020 | ||
PL | 12.08.2020 | ||
RO | 12.08.2020 | ||
RS | 12.08.2020 | ||
SE | 12.08.2020 | ||
SM | 12.08.2020 | ||
BG | 12.11.2020 | ||
NO | 12.11.2020 | ||
GR | 13.11.2020 | ||
IS | 12.12.2020 | ||
Former [2021/22] | CZ | 12.08.2020 | |
DK | 12.08.2020 | ||
EE | 12.08.2020 | ||
FI | 12.08.2020 | ||
HR | 12.08.2020 | ||
LT | 12.08.2020 | ||
LV | 12.08.2020 | ||
NL | 12.08.2020 | ||
PL | 12.08.2020 | ||
RO | 12.08.2020 | ||
RS | 12.08.2020 | ||
SE | 12.08.2020 | ||
BG | 12.11.2020 | ||
NO | 12.11.2020 | ||
GR | 13.11.2020 | ||
IS | 12.12.2020 | ||
Former [2021/21] | DK | 12.08.2020 | |
FI | 12.08.2020 | ||
HR | 12.08.2020 | ||
LT | 12.08.2020 | ||
LV | 12.08.2020 | ||
NL | 12.08.2020 | ||
PL | 12.08.2020 | ||
RS | 12.08.2020 | ||
SE | 12.08.2020 | ||
BG | 12.11.2020 | ||
NO | 12.11.2020 | ||
GR | 13.11.2020 | ||
IS | 12.12.2020 | ||
Former [2021/12] | FI | 12.08.2020 | |
HR | 12.08.2020 | ||
LT | 12.08.2020 | ||
LV | 12.08.2020 | ||
NL | 12.08.2020 | ||
PL | 12.08.2020 | ||
RS | 12.08.2020 | ||
SE | 12.08.2020 | ||
BG | 12.11.2020 | ||
NO | 12.11.2020 | ||
GR | 13.11.2020 | ||
IS | 12.12.2020 | ||
Former [2021/10] | FI | 12.08.2020 | |
HR | 12.08.2020 | ||
LT | 12.08.2020 | ||
LV | 12.08.2020 | ||
PL | 12.08.2020 | ||
RS | 12.08.2020 | ||
SE | 12.08.2020 | ||
BG | 12.11.2020 | ||
NO | 12.11.2020 | ||
GR | 13.11.2020 | ||
IS | 12.12.2020 | ||
Former [2021/09] | FI | 12.08.2020 | |
LT | 12.08.2020 | ||
SE | 12.08.2020 | ||
BG | 12.11.2020 | ||
NO | 12.11.2020 | ||
GR | 13.11.2020 | ||
Former [2021/08] | FI | 12.08.2020 | |
LT | 12.08.2020 | ||
SE | 12.08.2020 | ||
BG | 12.11.2020 | ||
NO | 12.11.2020 | ||
Former [2021/07] | FI | 12.08.2020 | |
LT | 12.08.2020 | ||
NO | 12.11.2020 | Documents cited: | Search | [XI]WO2009006389 (SUNESIS PHARMACEUTICALS INC [US], et al) [X] 1-3,7-9,15 * abstract * * page 48, paragraph 126 - page 49, paragraph 127 * * page 168; compound 10Da * * claims 1-30 * [I] 4-6,10-14; | [X]WO2010064722 (TAKEDA PHARMACEUTICAL [JP], et al) [X] 1-7,15 * abstract * * page 77, line 1 - page 79, line 2; example 53; claims 1,18,24-26 *; | [XP] - "A Phase 1B Study of MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Participants With Advanced Nonhematologic Malignancies", (20141230), ClinicalTrials.gov, URL: https://clinicaltrials.gov/ct2/show/NCT02327169, (20180820), XP002784013 [XP] 1-15 * the whole document * | [XI] - BALANI S K ET AL, "Drug drug interaction predictions for MLN2480, an investigational pan-RAF inhibitor, based on nonclinical data", EUROPEAN JOURNAL OF CANCER, & 26TH EORTC-NCI-AACR SYMPOSIUM ON MOLECULAR TARGETS AND CANCER THERAPEUTICS; BARCELONA, SPAIN; NOVEMBER 18 -21, 2014, (201411), vol. 50, no. Suppl. 6, ISSN 0959-8049, pages 54 - 55, XP002784014 [X] 1-3,7-9,15 * Abstract 162 * [I] 4-6,10-14 | [A] - MASANORI OKANIWA ET AL, "Discovery of a Selective Kinase Inhibitor (TAK-632) Targeting Pan-RAF Inhibition: Design, Synthesis, and Biological Evaluation of C -7-Substituted 1,3-Benzothiazole Derivatives", JOURNAL OF MEDICINAL CHEMISTRY, (20130801), vol. 56, no. 16, doi:10.1021/jm400778d, ISSN 0022-2623, pages 6478 - 6494, XP055500984 [A] 1-7,15 * the whole document * DOI: http://dx.doi.org/10.1021/jm400778d | International search | [Y]WO2009018238 (ARDEA BIOSCIENCES INC [US], et al) [Y] 14, 15 * entire document *; | [XY]US2010183600 (LAPIERRE JEAN-MARC [US], et al) [X] 1, 2, 17 * entire document * [Y] 3, 10-15, 18; | [Y]US2012214828 (HATZIVASSILIOU GEORGIA [US], et al) [Y] 11-13 * entire document *; | [Y]WO2013144923 (TAKEDA PHARMACEUTICAL [JP]) [Y] 3, 10-15, 18 * entire document *; | [PX]WO2015148828 (MILLENNIUM PHARM INC [US]) [PX] 1-3, 10-15, 17, 18* entire document * |